Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 254

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 254
---
 he had heard about Vaximm’s (a subsidiary of OSR Holdings) recent activity developing therapeutics in the glioblastoma space in Switzerland. Parent D’s CFO is not a scientist by training nor a professional with specific pharmaceutical drug development expertise but is experienced in the Korean capital markets/finance industry. The CFO of Parent D and Mr. Hwang also share a mutual acquaintance. As of late July 2023, OSR Holdings planned to have discussions with Parent D and Company D representatives regarding a potential business combination, and other potentially mutually beneficial business opportunities and synergies. Based on timing considerations and the need to proceed with an identified target company, the decision was made to cease discussions with Company D. Company E On April 17, 2023, another potential target company (“Company E”) was introduced to BLAC by Mr. Whang through an acquaintance, an independent investor and consultant based in New York City and Seoul (“Investor E”). Mr. Whang had told Investor E about BLAC’s February 14, 2023 IPO, and the need to execute a business combination by November 14, 2023, and Investor E informed Mr. Whang that he knew some companies that might be interested in a business combination opportunity with BLAC. Company E focuses on oral cancer diagnostics and therapeutics. On April 18 and21, 2023, Mr. Whang forwarded Company E’s non -confidentialinformation to BLAC and OSR Holdings for review. Initial review by BLAC and OSR Holdings included assessment of Korean companies with competing or comparable technology. Mr. Whang had further communications with Investor E through May 4, 2023. BLAC determined that Company E was not a viable candidate for a business combination, as the competitive landscape in the dental scanning technology space in Korea was too difficult to penetrate. Company F On April 17, 2023, another potential target company (“Company F”) was introduced to BLAC by Mr. Whang through Investor E. Company F develops novel diagnostic tests for cancer, including a urine test for bladder cancer. On April 18, 2023, Mr. Whang shared publicly available information on Company F with BLAC and OSR Holdings. Mr. Whang had further communications with Investor E through May 4, 2023. BLAC determined that Company F was not a viable candidate for a business combination, as OSR Holdings is focused primarily on drug development, while Company F is in the diagnostics space. Others In addition to